Latest Genmab News & Updates

See the latest news and media coverage for Genmab. We track all announcements, press releases, and industry mentions in real time, all in one place.

Genmab

Therapeutic antibody developer

genmab.com

Headquarters: 2500 Valby, Denmark
Company type: Public company
Number of employees: 3,000–5,000
Industry: Pharmaceuticals

Last updated Today

Latest news about Genmab

In short: Genmab achieved significant growth in 2026, punctuated by a $1.8 billion acquisition of ProfoundBio and key EU approvals for Tepkinly.

Company announcements

July 23 Genmab

Genmab and AbbVie clarify trial missed OS endpoint

The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab in relapsed/refractory DLBCL; overall survival, the US primary endpoint, was not met.

July 15 Genmab

Genmab reports Q2 2026 DARZALEX net sales of USD 4,207 million

Sales were USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world. Genmab receives royalties from Johnson & Johnson.

July 6 Genmab

Genmab announces European Commission approval of TEPKINLY combination for follicular lymphoma

The bispecific antibody plus lenalidomide and rituximab offers a chemotherapy-free option, reducing risk of progression by 79% in the Phase 3 trial.

June 29 Genmab

Genmab announces positive Phase 3 results for epcoritamab plus lenalidomide

The combination showed statistically significant improvement in progression-free survival in relapsed/refractory DLBCL patients.

Media coverage

July 28 AK&M

Danish biotech company Genmab acquires Dutch Merus for $8 billion

The Danish biotech company Genmab A/S has entered into an agreement to acquire the Dutch Merus NV. This is reported in the Genmab press release...

July 28 FinanzNachrichten.de

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B2 of the Phase 1/2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S, an investigational folate receptor...

July 23 MarketWatch

Genmab, AbbVie Say Lymphoma Drug Failed to Meet Primary Endpoint in Phase 3 Trial

A drug co-developed by Genmab and AbbVie to treat a certain type of lymphoma failed to meet its primary endpoint in a Phase 3 trial...

July 15 Euroinvestor

DSV received massive price hits, while Genmab rose after recommendation: This is how the trading day went

Wednesday was another day of price hits for Danish stocks, which have only become less valuable since the week started. Danish stocks fell by 2.0 percent...

Never miss news about Genmab

Track Genmab and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Genmab competitors & trending companies

Browse news for competitors to Genmab and other trending companies.